EMERYVILLE, Calif. and HUENENBERG, Switzerland, April 30, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (AMEX:NBY) announced today that the latest public data on its Aganocide® compounds, a new class of broad-spectrum antimicrobials, will be presented during three poster sessions at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida.
